Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Covalon Technologies Ltd V.COV

Alternate Symbol(s):  CVALF

Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon’s name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.


TSXV:COV - Post by User

Bullboard Posts
Comment by zenvestingon Oct 30, 2014 10:42am
70 Views
Post# 23076350

RE:RE:Dual antimicrobial products are best in class infection ctrl

RE:RE:Dual antimicrobial products are best in class infection ctrlWhy don't you reference their actual financial results, like the 54% gross margins last quarter, or that they earned $0.02 EPS in Q3/2013 on mostly wound care revenues.

You should also go tell 3M they're wasting their time trying to sell their 3M PICC / CVC Securement dressings into the vascualr access market, because as you imply, vascular access companies only have one supplier for their whole operation, they have to order their office supplies, sanitary supplies, PPE, and everything from the same company they get their catheters from, right?  


Bullboard Posts